
## Coleen K Cunningham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10929474/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Non-diphtheriae <i>Corynebacterium</i> species are associated with decreased risk of pneumococcal colonization during infancy. ISME Journal, 2022, 16, 655-665.	9.8	14
2	Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine. PLoS ONE, 2022, 17, e0262225.	2.5	5
3	Sauti ya Vijana (SYV; The Voice of Youth): Longitudinal Outcomes of an Individually Randomized Group Treatment Pilot Trial for Young People Living with HIV in Tanzania. AIDS and Behavior, 2022, 26, 2015-2025.	2.7	3
4	A group-based mental health intervention for Tanzanian youth living with HIV. Medicine (United) Tj ETQq0 0 0 rgE	3T_/Overlo 1.0	ck_10 Tf 50 (
5	Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2022, 225, 1731-1740.	4.0	5
6	Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children. Journal of Infectious Diseases, 2022, 226, 2069-2078.	4.0	12
7	Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clinical Infectious Diseases, 2021, 73, e2875-e2882.	5.8	51
8	Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 363-366.	1.3	1
9	Live-attenuated Vaccines Prevent Respiratory Syncytial Virus–associated Illness in Young Children. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 594-603.	5.6	37
10	SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatric Research, 2021, 90, 966-970.	2.3	27
11	Transcriptional and Immunologic Correlates of Response to Pandemic Influenza Vaccine in Aviremic, HIV-Infected Children. Frontiers in Immunology, 2021, 12, 639358.	4.8	2
12	Tar Heel Footprints in Health Care. North Carolina Medical Journal, 2021, 82, 93-94.	0.2	1
13	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1–Exposed Newborn Infants. Journal of Infectious Diseases, 2021, 224, 1916-1924.	4.0	27
14	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. Journal of Infectious Diseases, 2020, 222, 628-636.	4.0	38
15	Placental Transfer of Respiratory Syncytial Virus Antibody Among HIV-Exposed, Uninfected Infants. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 349-356.	1.3	11
16	Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children. Journal of Infectious Diseases, 2020, 221, 534-543.	4.0	28
17	A group-based mental health intervention for young people living with HIV in Tanzania: results of a pilot individually randomized group treatment trial. BMC Public Health, 2020, 20, 1358.	2.9	33
18	A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 596-608.	1.3	29

#	Article	IF	CITATIONS
19	Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children. Journal of Infectious Diseases, 2020, 221, 2050-2059.	4.0	31
20	Investigating Mediators of the Poor Pneumonia Outcomes of Human Immunodeficiency Virus–Exposed but Uninfected Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 13-20.	1.3	7
21	Challenges and facilitators of transition from adolescent to adult HIV care among young adults living with HIV in Moshi, Tanzania. Journal of the International AIDS Society, 2019, 22, e25406.	3.0	13
22	Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated. Open Forum Infectious Diseases, 2019, 6, ofz212.	0.9	17
23	Predictors of Poor Outcomes Among Infants With Respiratory Syncytial Virus–associated Acute Lower Respiratory Infection in Botswana. Pediatric Infectious Disease Journal, 2019, 38, 525-527.	2.0	4
24	The prevalence and clinical characteristics of pertussis-associated pneumonia among infants in Botswana. BMC Pediatrics, 2019, 19, 444.	1.7	2
25	HIV-1 Drug Resistance and Virologic Outcomes Among Tanzanian Youth Living With HIV. Pediatric Infectious Disease Journal, 2019, 38, 617-619.	2.0	5
26	Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth. Aids, 2019, 33, 211-218.	2.2	18
27	Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children. Journal of Infectious Diseases, 2018, 217, 1338-1346.	4.0	46
28	Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children. Journal of Infectious Diseases, 2018, 217, 1347-1355.	4.0	55
29	Anti–Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. Journal of Infectious Diseases, 2018, 218, 555-562.	4.0	34
30	Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. Aids, 2018, 32, 1115-1123.	2.2	25
31	Modality of Primary HIV Disclosure and Association with Mental Health, Stigma, and Antiretroviral Therapy Adherence in Tanzanian Youth Living with HIV. AIDS Patient Care and STDs, 2018, 32, 31-37.	2.5	23
32	Influence of Reported Penicillin Allergy on Mortality in MSSA Bacteremia. Open Forum Infectious Diseases, 2018, 5, ofy042.	0.9	18
33	Caregiver role in HIV medication adherence among HIV-infected orphans in Tanzania. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 701-705.	1.2	25
34	Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana. Pediatric Infectious Disease Journal, 2018, 37, 1176-1183.	2.0	11
35	Building resilience: a mental health intervention for Tanzanian youth living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 12-20.	1.2	44
36	Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. Vaccine, 2018, 36, 5600-5608.	3.8	21

COLEEN K CUNNINGHAM

#	Article	IF	CITATIONS
37	Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After Resolution of Acute Ebola Virus Infection. Open Forum Infectious Diseases, 2017, 4, ofx155.	0.9	46
38	The Nasopharyngeal Microbiota of Children With Respiratory Infections in Botswana. Pediatric Infectious Disease Journal, 2017, 36, e211-e218.	2.0	49
39	HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania. AIDS Research and Human Retroviruses, 2017, 33, 1107-1113.	1.1	5
40	Apheresis for collection of Ebola convalescent plasma in Liberia. Journal of Clinical Apheresis, 2017, 32, 175-181.	1.3	16
41	Is MMTV associated with human breast cancer? Maybe, but probably not. Virology Journal, 2017, 14, 196.	3.4	11
42	A Qualitative Exploration of the Mental Health and Psychosocial Contexts of HIV-Positive Adolescents in Tanzania. PLoS ONE, 2016, 11, e0165936.	2.5	44
43	Impact of Reported Penicillin Allergy in Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
44	Chest Radiographic Findings and Outcomes of Pneumonia Among Children in Botswana. Pediatric Infectious Disease Journal, 2016, 35, 257-262.	2.0	20
45	Evaluating mental health difficulties and associated outcomes among HIV-positive adolescents in Tanzania. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 825-833.	1.2	117
46	Hyper IgM Syndrome: a Report from the USIDNET Registry. Journal of Clinical Immunology, 2016, 36, 490-501.	3.8	92
47	Response. Clinical Trials, 2016, 13, 568-569.	1.6	1
48	A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response. Clinical Trials, 2016, 13, 22-30.	1.6	50
49	Establishment of biochemistry reference values for healthy Tanzanian infants, children and adolescents in Kilimanjaro Region. Tropical Medicine and International Health, 2015, 20, 1569-1577.	2.3	14
50	Characterization of Functional Antibody and Memory B-Cell Responses to pH1N1 Monovalent Vaccine in HIV-Infected Children and Youth. PLoS ONE, 2015, 10, e0118567.	2.5	15
51	Association of Respiratory Viruses with Outcomes of Severe Childhood Pneumonia in Botswana. PLoS ONE, 2015, 10, e0126593.	2.5	33
52	Infant HIV-1 Vaccines. JAMA - Journal of the American Medical Association, 2015, 313, 1513.	7.4	7
53	Treatment Failures and Excess Mortality Among HIV-Exposed, Uninfected Children With Pneumonia. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e117-e126.	1.3	46
54	Progress in the Prevention of Mother to Child Transmission of HIV in Three Regions of Tanzania: A Retrospective Analysis. PLoS ONE, 2014, 9, e88679.	2.5	18

## COLEEN K CUNNINGHAM

#	Article	IF	CITATIONS
55	A Review of Human Herpesvirus 8, the Kaposi's Sarcoma-Associated Herpesvirus, in the Pediatric Population. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 66-76.	1.3	41
56	HIV Type 1 (HIV-1) Proviral Reservoirs Decay Continuously Under Sustained Virologic Control in HIV-1–Infected Children Who Received Early Treatment. Journal of Infectious Diseases, 2014, 210, 1529-1538.	4.0	123
57	HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission. PLoS Medicine, 2014, 11, e1001616.	8.4	29
58	Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. BMC Infectious Diseases, 2014, 14, 567.	2.9	31
59	Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 352-360.	1.3	10
60	High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). Human Vaccines and Immunotherapeutics, 2013, 9, 957-968.	3.3	15
61	Comprehension of a simplified assent form in a vaccine trial for adolescents: TableÂ1. Journal of Medical Ethics, 2013, 39, 410-412.	1.8	13
62	Seroprevalence of Hepatitis B and C Viruses Among Children in Kilimanjaro Region, Tanzania. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 320-326.	1.3	16
63	Safety and Immunogenicity of 2009 Pandemic H1N1 Influenza Vaccination in Perinatally HIV-1-Infected Children, Adolescents, and Young Adults. Journal of Infectious Diseases, 2012, 206, 421-430.	4.0	24
64	Initial HIV-1 Antigen-Specific CD8 <sup>+</sup> T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication. Journal of Virology, 2012, 86, 6835-6846.	3.4	56
65	Invasive bacterial and fungal infections among hospitalized HIVâ€infected and HIVâ€uninfected children and infants in northern Tanzania. Tropical Medicine and International Health, 2011, 16, 830-837.	2.3	78
66	Secretion of MIP-1β and MIP-1α by CD8+ T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. Cellular Immunology, 2011, 266, 154-164.	3.0	28
67	Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. Journal of Perinatal Medicine, 2011, 39, 163-70.	1.4	35
68	Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. Aids, 2011, 25, 2227-2234.	2.2	30
69	Predicting Virologic Failure Among HIV-1-Infected Children Receiving Antiretroviral Therapy in Tanzania: a Cross-Sectional Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 368-375.	2.1	70
70	Birth Defects Among Children Born to Human Immunodeficiency Virus-Infected Women. Pediatric Infectious Disease Journal, 2010, 29, 721-727.	2.0	90
71	Epigenetic regulation of CD8+ T-lymphocyte mediated suppression of HIV-1 replication. Virology, 2010, 405, 234-242.	2.4	15
72	Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region. Tropical Medicine and International Health, 2010, 15, no-no.	2.3	67

#	Article	IF	CITATIONS
73	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. Journal of Virology, 2010, 84, 4998-5006.	3.4	110
74	Randomized Trial to Determine Safety and Immunogenicity of Two Strategies for Hepatitis B Vaccination in Healthy Urban Adolescents in the United States. Pediatric Infectious Disease Journal, 2010, 29, 530-534.	2.0	5
75	Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy. Journal of Virology, 2009, 83, 9731-9742.	3.4	41
76	Advances and Failures in Preventing Perinatal Human Immunodeficiency Virus Infection. Clinical Microbiology Reviews, 2009, 22, 493-507.	13.6	18
77	Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine, 2008, 26, 6883-6893.	3.8	38
78	Inclusion of Adolescents in Preventive HIV Vaccine Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 86-92.	2.1	40
79	Vaccines for prevention of mother-to-child transmission of HIV. Current Opinion in HIV and AIDS, 2008, 3, 151-154.	3.8	9
80	Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environmental and Molecular Mutagenesis, 2007, 48, 322-329.	2.2	59
81	Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infectious Diseases, 2007, 7, 60.	2.9	20
82	Maternal toxicity and pregnancy complications in human immunodeficiency virus–infected women receiving antiretroviral therapy: PACTG 316. American Journal of Obstetrics and Gynecology, 2004, 190, 506-516.	1.3	97
83	The Impact of Race/Ethnicity on Mother-to-Child HIV Transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 800-807.	2.1	14
84	Predose Infant Nevirapine Concentration With the Two-Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine Dose. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 153-156.	2.1	56
85	Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316. Journal of Infectious Diseases. 2002. 186. 181-188.	4.0	117
86	Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2002, 288, 189.	7.4	317
87	Early Language Development in Children Exposed to or Infected With Human Immunodeficiency Virus. Pediatrics, 1998, 102, e8-e8.	2.1	38
88	Respiratory Syncytial Virus and Influenza A Infections in the Hospitalized Elderly. Journal of Infectious Diseases, 1995, 172, 389-394.	4.0	358